A Tale of Two Checkpoints: ATR Inhibition and PD-(L)1 Blockade
Innate immunity and the DNA damage response (DDR) pathway are inextricably linked. Within the DDR, ataxia telangiectasia and Rad3-related (ATR) is a key kinase responsible for sensing replication stress and facilitating DNA repair through checkpoint activation, cell cycle arrest, and promotion of fo...
Gespeichert in:
| Veröffentlicht in: | Annual review of medicine 2022-01, Vol.73 (1), p.231-250 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 250 |
|---|---|
| container_issue | 1 |
| container_start_page | 231 |
| container_title | Annual review of medicine |
| container_volume | 73 |
| creator | Ngoi, Natalie Y.L Peng, Guang Yap, Timothy A |
| description | Innate immunity and the DNA damage response (DDR) pathway are inextricably linked. Within the DDR, ataxia telangiectasia and Rad3-related (ATR) is a key kinase responsible for sensing replication stress and facilitating DNA repair through checkpoint activation, cell cycle arrest, and promotion of fork recovery. Recent studies have shed light on the immunomodulatory role of the ATR-CHK1 pathway in the tumor microenvironment and the specific effects of ATR inhibition in stimulating an innate immune response. With several potent and selective ATR inhibitors in developmental pipelines, the combination of dual ATR and PD-(L)1 blockade has attracted increasing interest in cancer therapy. In this review, we summarize the clinical and preclinical data supporting the combined inhibition of ATR and PD-(L)1, discuss the potential challenges surrounding this approach, and highlight biomarkers relevant for selected patients who are most likely to benefit from the blockade of these two checkpoints. |
| doi_str_mv | 10.1146/annurev-med-042320-025136 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_34644155</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2656848458</sourcerecordid><originalsourceid>FETCH-LOGICAL-a3666-726b6efa22f135d3fde44560021abe432999c28bedcaf1f337172e4e4ca2ae763</originalsourceid><addsrcrecordid>eNqVkMtKw0AUhgdRbL28goy4qYvo3JO4KNR6KxQUieBumCQnNG2aqZnG4ts7Je3GnauzON__n8OH0CUlN5QKdWvqum3gO1hCHhDBOCMBYZJydYD6VAoZcKY-D1GfEKUCwWjcQyfOzQkhMefRMepxoYSgUvbRcIQTUwG2BU42Fo9nkC1WtqzX7g6Pknc8qWdlWq5LW2NT5_jtIRhMrym-r2y2MDmcoaPCVA7Od_MUfTw9JuOXYPr6PBmPpoHhyv8QMpUqKAxjBeUy50UOQkhFCKMmBcFZHMcZi1LIM1PQgvOQhgwEiMwwA6Hip2jQ9a4a-9WCW-tl6TKoKlODbZ1mMmLUCwhjj179Qee2bWr_nWZKqkhEQkaeijsqa6xzDRR61ZRL0_xoSvRWst5J1l6y7iTrTrLPXuwutOl2u0_urXpg2AHbDlP5lhI27h8XfgFe24yh</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2656848458</pqid></control><display><type>article</type><title>A Tale of Two Checkpoints: ATR Inhibition and PD-(L)1 Blockade</title><source>Annual Reviews Complete A-Z List</source><creator>Ngoi, Natalie Y.L ; Peng, Guang ; Yap, Timothy A</creator><creatorcontrib>Ngoi, Natalie Y.L ; Peng, Guang ; Yap, Timothy A</creatorcontrib><description>Innate immunity and the DNA damage response (DDR) pathway are inextricably linked. Within the DDR, ataxia telangiectasia and Rad3-related (ATR) is a key kinase responsible for sensing replication stress and facilitating DNA repair through checkpoint activation, cell cycle arrest, and promotion of fork recovery. Recent studies have shed light on the immunomodulatory role of the ATR-CHK1 pathway in the tumor microenvironment and the specific effects of ATR inhibition in stimulating an innate immune response. With several potent and selective ATR inhibitors in developmental pipelines, the combination of dual ATR and PD-(L)1 blockade has attracted increasing interest in cancer therapy. In this review, we summarize the clinical and preclinical data supporting the combined inhibition of ATR and PD-(L)1, discuss the potential challenges surrounding this approach, and highlight biomarkers relevant for selected patients who are most likely to benefit from the blockade of these two checkpoints.</description><identifier>ISSN: 0066-4219</identifier><identifier>EISSN: 1545-326X</identifier><identifier>DOI: 10.1146/annurev-med-042320-025136</identifier><identifier>PMID: 34644155</identifier><language>eng</language><publisher>United States: Annual Reviews</publisher><subject>Ataxia telangiectasia ; ATR inhibitors ; cancer therapy ; Cell activation ; Cell cycle ; CHK1 protein ; Deoxyribonucleic acid ; DNA ; DNA biosynthesis ; DNA damage ; DNA repair ; drug development ; immune checkpoint blockade ; immune modulation ; Immune response ; Immunomodulation ; Innate immunity ; Tumor microenvironment ; Tumors</subject><ispartof>Annual review of medicine, 2022-01, Vol.73 (1), p.231-250</ispartof><rights>Copyright Annual Reviews, Inc. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a3666-726b6efa22f135d3fde44560021abe432999c28bedcaf1f337172e4e4ca2ae763</citedby><cites>FETCH-LOGICAL-a3666-726b6efa22f135d3fde44560021abe432999c28bedcaf1f337172e4e4ca2ae763</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.annualreviews.org/content/journals/10.1146/annurev-med-042320-025136?crawler=true&mimetype=application/pdf$$EPDF$$P50$$Gannualreviews$$H</linktopdf><linktohtml>$$Uhttps://www.annualreviews.org/content/journals/10.1146/annurev-med-042320-025136$$EHTML$$P50$$Gannualreviews$$H</linktohtml><link.rule.ids>70,314,776,780,4168,27901,27902,78223,78224</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34644155$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ngoi, Natalie Y.L</creatorcontrib><creatorcontrib>Peng, Guang</creatorcontrib><creatorcontrib>Yap, Timothy A</creatorcontrib><title>A Tale of Two Checkpoints: ATR Inhibition and PD-(L)1 Blockade</title><title>Annual review of medicine</title><addtitle>Annu Rev Med</addtitle><description>Innate immunity and the DNA damage response (DDR) pathway are inextricably linked. Within the DDR, ataxia telangiectasia and Rad3-related (ATR) is a key kinase responsible for sensing replication stress and facilitating DNA repair through checkpoint activation, cell cycle arrest, and promotion of fork recovery. Recent studies have shed light on the immunomodulatory role of the ATR-CHK1 pathway in the tumor microenvironment and the specific effects of ATR inhibition in stimulating an innate immune response. With several potent and selective ATR inhibitors in developmental pipelines, the combination of dual ATR and PD-(L)1 blockade has attracted increasing interest in cancer therapy. In this review, we summarize the clinical and preclinical data supporting the combined inhibition of ATR and PD-(L)1, discuss the potential challenges surrounding this approach, and highlight biomarkers relevant for selected patients who are most likely to benefit from the blockade of these two checkpoints.</description><subject>Ataxia telangiectasia</subject><subject>ATR inhibitors</subject><subject>cancer therapy</subject><subject>Cell activation</subject><subject>Cell cycle</subject><subject>CHK1 protein</subject><subject>Deoxyribonucleic acid</subject><subject>DNA</subject><subject>DNA biosynthesis</subject><subject>DNA damage</subject><subject>DNA repair</subject><subject>drug development</subject><subject>immune checkpoint blockade</subject><subject>immune modulation</subject><subject>Immune response</subject><subject>Immunomodulation</subject><subject>Innate immunity</subject><subject>Tumor microenvironment</subject><subject>Tumors</subject><issn>0066-4219</issn><issn>1545-326X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNqVkMtKw0AUhgdRbL28goy4qYvo3JO4KNR6KxQUieBumCQnNG2aqZnG4ts7Je3GnauzON__n8OH0CUlN5QKdWvqum3gO1hCHhDBOCMBYZJydYD6VAoZcKY-D1GfEKUCwWjcQyfOzQkhMefRMepxoYSgUvbRcIQTUwG2BU42Fo9nkC1WtqzX7g6Pknc8qWdlWq5LW2NT5_jtIRhMrym-r2y2MDmcoaPCVA7Od_MUfTw9JuOXYPr6PBmPpoHhyv8QMpUqKAxjBeUy50UOQkhFCKMmBcFZHMcZi1LIM1PQgvOQhgwEiMwwA6Hip2jQ9a4a-9WCW-tl6TKoKlODbZ1mMmLUCwhjj179Qee2bWr_nWZKqkhEQkaeijsqa6xzDRR61ZRL0_xoSvRWst5J1l6y7iTrTrLPXuwutOl2u0_urXpg2AHbDlP5lhI27h8XfgFe24yh</recordid><startdate>20220127</startdate><enddate>20220127</enddate><creator>Ngoi, Natalie Y.L</creator><creator>Peng, Guang</creator><creator>Yap, Timothy A</creator><general>Annual Reviews</general><general>Annual Reviews, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7T5</scope><scope>7TO</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20220127</creationdate><title>A Tale of Two Checkpoints: ATR Inhibition and PD-(L)1 Blockade</title><author>Ngoi, Natalie Y.L ; Peng, Guang ; Yap, Timothy A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a3666-726b6efa22f135d3fde44560021abe432999c28bedcaf1f337172e4e4ca2ae763</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Ataxia telangiectasia</topic><topic>ATR inhibitors</topic><topic>cancer therapy</topic><topic>Cell activation</topic><topic>Cell cycle</topic><topic>CHK1 protein</topic><topic>Deoxyribonucleic acid</topic><topic>DNA</topic><topic>DNA biosynthesis</topic><topic>DNA damage</topic><topic>DNA repair</topic><topic>drug development</topic><topic>immune checkpoint blockade</topic><topic>immune modulation</topic><topic>Immune response</topic><topic>Immunomodulation</topic><topic>Innate immunity</topic><topic>Tumor microenvironment</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ngoi, Natalie Y.L</creatorcontrib><creatorcontrib>Peng, Guang</creatorcontrib><creatorcontrib>Yap, Timothy A</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Annual review of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ngoi, Natalie Y.L</au><au>Peng, Guang</au><au>Yap, Timothy A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Tale of Two Checkpoints: ATR Inhibition and PD-(L)1 Blockade</atitle><jtitle>Annual review of medicine</jtitle><addtitle>Annu Rev Med</addtitle><date>2022-01-27</date><risdate>2022</risdate><volume>73</volume><issue>1</issue><spage>231</spage><epage>250</epage><pages>231-250</pages><issn>0066-4219</issn><eissn>1545-326X</eissn><abstract>Innate immunity and the DNA damage response (DDR) pathway are inextricably linked. Within the DDR, ataxia telangiectasia and Rad3-related (ATR) is a key kinase responsible for sensing replication stress and facilitating DNA repair through checkpoint activation, cell cycle arrest, and promotion of fork recovery. Recent studies have shed light on the immunomodulatory role of the ATR-CHK1 pathway in the tumor microenvironment and the specific effects of ATR inhibition in stimulating an innate immune response. With several potent and selective ATR inhibitors in developmental pipelines, the combination of dual ATR and PD-(L)1 blockade has attracted increasing interest in cancer therapy. In this review, we summarize the clinical and preclinical data supporting the combined inhibition of ATR and PD-(L)1, discuss the potential challenges surrounding this approach, and highlight biomarkers relevant for selected patients who are most likely to benefit from the blockade of these two checkpoints.</abstract><cop>United States</cop><pub>Annual Reviews</pub><pmid>34644155</pmid><doi>10.1146/annurev-med-042320-025136</doi><tpages>20</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0066-4219 |
| ispartof | Annual review of medicine, 2022-01, Vol.73 (1), p.231-250 |
| issn | 0066-4219 1545-326X |
| language | eng |
| recordid | cdi_pubmed_primary_34644155 |
| source | Annual Reviews Complete A-Z List |
| subjects | Ataxia telangiectasia ATR inhibitors cancer therapy Cell activation Cell cycle CHK1 protein Deoxyribonucleic acid DNA DNA biosynthesis DNA damage DNA repair drug development immune checkpoint blockade immune modulation Immune response Immunomodulation Innate immunity Tumor microenvironment Tumors |
| title | A Tale of Two Checkpoints: ATR Inhibition and PD-(L)1 Blockade |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-18T09%3A46%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Tale%20of%20Two%20Checkpoints:%20ATR%20Inhibition%20and%20PD-(L)1%20Blockade&rft.jtitle=Annual%20review%20of%20medicine&rft.au=Ngoi,%20Natalie%20Y.L&rft.date=2022-01-27&rft.volume=73&rft.issue=1&rft.spage=231&rft.epage=250&rft.pages=231-250&rft.issn=0066-4219&rft.eissn=1545-326X&rft_id=info:doi/10.1146/annurev-med-042320-025136&rft_dat=%3Cproquest_pubme%3E2656848458%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2656848458&rft_id=info:pmid/34644155&rfr_iscdi=true |